Health
Biocompatible photooxygenation catalyst could be potentially used to treat amyloid diseases – News-Medical.Net
A new, biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer’s disease (AD)-related amyloid-β…
Reviewed by Emily Henderson, B.Sc.Nov 25 2020
A new, biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer’s disease (AD)-related amyloid-β peptide (Aβ) under near-infrared (NIR) light irradiation is developed.
The catalyst was able to oxygenate Aβ embedded under the skin of a living mouse, and diminished intact Aβ level in AD-model mouse brain. The new catalyst is potentially applicable for the treatment of peripheral amyloid…
-
Business20 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News17 hours agoWilliam Robinson dies aged 89
-
Business18 hours agoTop brokers name 3 ASX shares to buy today 27 August 2025
-
Business21 hours agoThis ASX 200 media stock is storming 7% higher to 52-week highs. Here’s why.